Publications by authors named "Raphael Lievin"
Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein-Barr virus (EBV)-related neoplasm preferentially involving the upper aerodigestive tract. Here we show that NK-cell-specific Trp53 disruption in mice leads to the development of NK-cell lymphomas after long latency, which involve not only the hematopoietic system but also the salivary glands. Before tumor onset, Trp53 knockout causes extensive gene expression changes, resulting in immature NK-cell expansion, exclusively in the salivary glands.
View Article and Find Full Text PDFArticle Synopsis
- HIV infection increases the risk of diffuse large B-cell lymphoma (DLBCL), and this study analyzed B-cell activating cytokines and T cell subsets in 51 HIV-associated DLBCL patients undergoing R-CHOP treatment.
- R-CHOP therapy led to decreased IL-10 and fluctuating IL-6 levels while BAFF levels initially rose and then fell; a significant increase in naïve B cells was observed, but recovery of other B cell types was gradual.
- With a median follow-up of 41 months, 5-year progression-free survival was 61.8% and overall survival was 67.4%, with main causes of death being disease progression and sepsis, highlighting the need for assessing B-cell disturbances in patient
Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein-Barr virus (EBV)-related neoplasm with male dominance and a poor prognosis. A better understanding of the genetic alterations and their functional roles in ENKTCL could help improve patient stratification and treatments. In this study, we performed a comprehensive genetic analysis of 178 ENKTCL cases to delineate the landscape of mutations, copy number alterations (CNA), and structural variations, identifying 34 driver genes including six previously unappreciated ones, namely, HLA-B, HLA-C, ROBO1, CD58, POT1, and MAP2K1.
View Article and Find Full Text PDFArticle Synopsis
- The COVID-19 pandemic has severely affected individuals with hematological malignancies due to their weakened immune systems, resulting in higher mortality rates and severe outcomes.
- Data from the EPICOVIDEHA registry, which compiles COVID-19 cases from these patients worldwide, was collected from 2020 to 2022, including 8,767 cases from 152 centers across 41 countries.
- Findings show a significant drop in critical infections and overall mortality rates, but hospitalization (especially in ICU) remains a serious risk factor; vaccination is linked to better survival outcomes, highlighting the need for ongoing monitoring and support for these patients.
Article Synopsis
- - Patients who had CD19-directed CAR T-cell therapy remain highly susceptible to viral infections, especially with COVID-19, which showed a 31% overall mortality rate in the study population.
- - Those infected with the Omicron variant had a significantly lower mortality risk (7%) compared to earlier variants (58%).
- - Vaccination and monoclonal antibody treatment were found to improve outcomes, with a marked reduction in mortality (from 32% to 0%) for those treated with monoclonal antibodies, indicating better survival rates for CAR T-cell recipients over time.
Article Synopsis
- * The Omicron variant was the most common strain detected (68.7%), with a notable 9% mortality rate within 30 days of diagnosis, which is lower compared to the pre-vaccine era's 31%.
- * Factors like older age, active HM, and severe COVID-19 increased mortality, while treatment with monoclonal antibodies reduced the death rate, demonstrating that even vaccinated patients with HM remain at significant risk for severe outcomes.
Article Synopsis
- Chimeric Antigen Receptor T cells (CAR-T) are a promising treatment for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), but come with significant toxicities like cytokine release syndrome (CRS) and neurotoxicity.
- A study compared patients who received early G-CSF (granulocyte-colony stimulating factor) after CAR-T infusion to those treated before this protocol; early administration significantly reduced febrile neutropenia rates without affecting the overall toxicity levels.
- The effectiveness of CAR-T in terms of T-cell expansion, response rates, and survival remained similar between both patient groups, indicating that early G-CSF is a safe strategy for managing side effects while preserving treatment efficacy.
Classical Hodgkin Lymphoma incidence increases in HIV-1-infected patients (HIV-cHL). HIV infection is associated with higher B-cell activation. Here, in 38 HIV-cHL patients from the French cohort ANRS-CO16 Lymphovir, we examined longitudinally over 24 months the serum levels of the B-cell activating cytokines IL10, IL6, and BAFF, and blood distribution of B-cell subsets.
View Article and Find Full Text PDFBackground: The detection of KMT2A gene rearrangements have an important impact on the prognosis and management of acute leukemias. These alterations most commonly involve reciprocal translocations at specific breakpoint regions within KMT2A. To date, more than 100 translocation partner genes of KMT2A have been identified, with different effects on risk stratification.
View Article and Find Full Text PDF